Institutional Area‚ Behind the Grand Hotel‚ Vasant Kunj‚ New Delhi – 110070 Tel.: 2612409090 / 91; Fax: 26124092 E-mail: administration@srisim.org; Website: www.srisim.org DEVELOPMENT DAY PROJECT REPORT STRATEGIC ALLIANCE IN INDIAN PHARMACEUTICAL INDUSTRY Submitted by: | Name: Jagriti Singh (20090123) Amardeep Tomar(20090106) Shilpa Jaiswal(20090155) Anil Chauhan(20090108) | Batch: | 2009 – 2011. | MANAGING THROUGH WISDOM INTRODUCTION
Premium Pharmaceutical industry Pharmacology Drug discovery
PERFORMANCE ANALYSIS OF BEXIMCO PHARMACEUTICALS LTD. Submitted By: Md. Fazlul Haque Executive Summary This report prepared to make a through analysis of the financial statements of Beximco Pharmaceuticals Ltd (BPL). The report mainly highlights the results of various ratio analysis of the company. In order to make the analysis more informative‚ inter-firm comparisons have also been provided by performing ratio analysis of other leading pharmaceutical companies in Bangladesh. It is hoped that
Premium Financial ratio Financial ratios Balance sheet
development & manufacturing processes in pharmaceutical R&D organizations Product Lifecycle Management for the Pharmaceutical Industry An Oracle White Paper Author: Todd Hein‚ Oracle Life Sciences Key Contributors: i. ii. iii. Arvindh Balakrishnan‚ Oracle Life Sciences Hardeep Gulati‚ Oracle Product Strategy Michael Winkler‚ Oracle Life Sciences Oracle Pharmaceutical Solution Set Page 1 Improving clinical development & manufacturing processes in pharmaceutical R&D organizations Introduction: In
Premium Clinical trial Pharmaceutical industry Pharmacology
Vyaderm Pharmaceuticals Case Analysis | | | As consultant to Sanders and Myers‚ I would suggest they rethink the continuation of economic value added (“EVA”) bonus payout process. The proposed EVA bonus payout structure is supposed to be an objective way to gauge and reward employee performance; however‚ through no fault of their own‚ the Dermatology group is slated to undergo severe ebbs and flows in their incentive and could potentially wreak havoc on employee morale and retention. For
Premium Mathematics Expense 2001
Amity International Business School Amity University Term Paper Report On Pharmaceutical Industry Submitted By: Akansha Neha Sandhu Rijul
Premium Pharmaceutical industry Pharmacology
Summer Internship Project In Depth Fundamental Analysis of Pharmaceutical Industry Submitted in partial fulfillment of PGDM program 2009-11 [pic] Submitted by Vikas Khandelwal 17/058 Company Guide Faculty Guide Name: Mr. Ritesh Purohit Name: Ms. Ruchi Paliwal Assistant Vice President Globe Capital Market Ltd. Apeejay School of Management New Delhi July 2010 ACKNOWLEDGEMENT This project would have been difficult to complete without the invaluable contributions
Premium Stock market Fundamental analysis Technical analysis
Teva Pharmaceuticals Strategy Overview 4/22/2013 PARTHIBAN SELVAM SMU MBA 2013 Business Overview: Teva Pharmaceuticals is a pharmaceutical company specializing in generic and proprietary drugs. It is the world’s 11th biggest pharmaceutical company. Apart from its major market‚ US and Europe‚ it has a major presence in Russia‚ Latin America‚ Japan and South Korea. In 2012‚ it had revenue of 20.3 billion and a net income of 1.96 billion (see table 1). Target Customers: Teva pharmaceutical’s
Premium Generic drug Pharmaceutical industry Pharmacology
Bangladesh pharmaceutical market in 2011 stood at approximately US $ 800 million‚ which is very small when compared to the population base of the country‚ which currently stands at about 140 million. To put this number on a proper perspective‚ the total global pharmaceutical sale in 2011 was $600 billion. This is expected to grow about $730 billion in 2013. Of course the majority of the sale in 2011 was in brand products‚ the market segment where Bangladesh does not or is not expected to participate
Premium Inflation Central Intelligence Agency Economic growth
Case No. 2: Pharmagen Pharmaceutical Development Funding According to the Accounting Standards Codification‚ the funding arrangement between Pharmagen (Pharma) and the private equity investor (PEI) would be applicable under the Research and Development Arrangements standard (ASC 730-20). This standard provides guidance for entities that are entered into a research and development (R&D) arrangement who acquire the results of research and development through the entire or partial funding by others
Premium Pharmacology Business Finance
Historical background of the business Today Merck & Co‚ Inc. is one of the most recognizable companies in the pharmaceutical industry. When asked about Merck‚ most people think that it is and always has been a US company. However‚ the company’s history can be traced all the way back to the 1600’s where it was started in Darmstadt‚ Germany. Friedrich Jacob Merck purchased a local store in 1668 where he prepared and sold medicines. The store was called “At the sign of the Angels” and would remain
Premium